BPC-157: Complete Research Guide

BPC-157, or Body Protection Compound-157, is a synthetic 15-amino acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protective protein found in human gastric juice. It was first identified and characterized by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s.

Unlike most peptides used in research, BPC-157 is stable in gastric acid — a property that distinguishes it from other bioactive peptides that degrade rapidly in the GI tract. This acid stability has been demonstrated in multiple studies and is attributed to the peptide's proline-rich sequence, which confers resistance to enzymatic degradation.

BPC-157 does not occur naturally as a standalone molecule. It is a partial sequence of a larger protein called Body Protection Compound (BPC), which is present in human gastric juice at nanogram-per-milliliter concentrations. The 15-amino acid fragment retains the biological activity of the parent protein in preclinical models, making it a practical tool for research into tissue-protective mechanisms.

BPC-157's biological activity involves multiple interconnected signaling pathways. Unlike single-target molecules, BPC-157 appears to modulate several systems simultaneously, which may account for the breadth of effects reported in preclinical literature.

The majority of BPC-157 research has focused on its tissue-protective and regenerative effects across multiple organ systems. The preclinical evidence spans tendon, ligament, muscle, bone, skin, and visceral organ repair.

BPC-157 has shown neuroprotective properties in several preclinical models of central and peripheral nervous system injury.

In traumatic brain injury (TBI) models, BPC-157 treatment reduced cerebral edema, decreased lesion volume, and improved neurobehavioral outcomes on standardized assessment scales. The effect was associated with reduced oxidative stress markers and decreased inflammatory cytokine levels in brain tissue.

In peripheral nerve crush injury models (sciatic nerve), BPC-157 accelerated nerve regeneration as measured by electrophysiological recovery (compound muscle action potential amplitude and latency) and histological assessment of axonal regrowth. Treated animals showed faster return of motor function compared to controls.

BPC-157 has also demonstrated protective effects against cuprizone-induced demyelination in mice — a model relevant to multiple sclerosis research. Treatment attenuated the loss of myelin basic protein (MBP) staining and preserved oligodendrocyte populations in the corpus callosum.

Additionally, studies have investigated BPC-157 in models of dopaminergic neuron loss relevant to Parkinson's disease research. In MPTP-treated mice, BPC-157 attenuated the loss of tyrosine hydroxylase-positive neurons in the substantia nigra and improved motor performance on rotarod testing.

BPC-157's cardiovascular research profile encompasses cardioprotection, vascular repair, and blood pressure modulation.

In ischemia-reperfusion injury models, BPC-157 reduced infarct size and improved post-ischemic cardiac function. The cardioprotective mechanism involves NO system modulation, reduction of reactive oxygen species (ROS) generation, and anti-apoptotic effects on cardiomyocytes.

BPC-157 also demonstrates significant effects on vascular repair. In models of abdominal aorta anastomosis, it improved anastomotic healing strength and endothelial regeneration. In thrombosis models, it counteracted the vascular occlusion caused by both venous and arterial thrombi.

Blood pressure modulation is another area of investigation. BPC-157 has been shown to normalize blood pressure in both hypertensive (L-NAME-induced) and hypotensive (L-arginine-induced) models, consistent with its bidirectional modulation of the NO system.

BPC-157 is available as a lyophilized powder that requires reconstitution with bacteriostatic water before use. Its acid stability distinguishes it from most research peptides and has implications for experimental design.

**Reconstitution:** BPC-157 is reconstituted by adding bacteriostatic water slowly along the vial wall and swirling gently. Do not shake, as this can damage the peptide. The reconstituted solution should be clear and colorless.

**Routes studied in literature:** The published research has used several administration routes, including intraperitoneal (i.p.), subcutaneous (s.c.), intragastric (i.g.), topical (cream formulation), and intra-articular injection. Notably, oral (intragastric) administration has been effective in GI models, reflecting the peptide's gastric acid stability.

**Dosing in preclinical models:** Published rodent studies have typically used doses of 10 mcg/kg to 10 mg/kg, with the most common effective range being 10–100 mcg/kg. Both single-dose and chronic administration protocols have been studied.

**Stability:** Unreconstituted lyophilized BPC-157 should be stored at -20C or 2-8C. Once reconstituted, it should be refrigerated at 2-8C and used within 28 days. BPC-157 is stable in solution at physiological pH for extended periods, and its gastric acid stability has been confirmed at pH values as low as 1.0.

BPC-157 has shown a favorable safety profile across the published preclinical literature. Key findings include:

**No reported LD50:** In toxicology studies, researchers have not been able to establish a lethal dose in rodents. Even at doses far exceeding the effective range (up to 10 mg/kg — roughly 1000x the typical effective dose), no mortality or organ toxicity was observed.

**No mutagenicity:** BPC-157 has tested negative in standard genotoxicity assays (Ames test, micronucleus assay).

**No effect on growth or body weight:** Chronic administration in rodent models has not shown effects on body weight, food intake, or growth patterns — suggesting an absence of significant hormonal or metabolic disruption.

**No observed drug interactions:** In combination studies with NSAIDs, corticosteroids, and alcohol, BPC-157 did not produce adverse interactions and in many cases counteracted the tissue-damaging effects of these agents.

It is important to note that the safety data is limited to preclinical animal models. No Phase I or Phase II clinical trials have been completed for BPC-157, so the human safety profile has not been formally established through controlled clinical studies.

BPC-157 and TB-500 are frequently compared because both peptides are studied for tissue repair. However, they differ in origin, mechanism, and research profile.

**Origin:** BPC-157 is derived from human gastric juice (a GI protective protein). TB-500 is a synthetic form of Thymosin Beta-4, a ubiquitous intracellular protein involved in actin sequestration.

**Primary mechanism:** BPC-157 modulates the NO system, growth factor expression, and multiple neurotransmitter systems. TB-500 primarily sequesters G-actin monomers, promoting cytoskeletal remodeling, cell migration, and angiogenesis.

**Acid stability:** BPC-157 is stable in gastric acid and effective via oral administration. TB-500 is not acid-stable and is typically administered by injection in research protocols.

**Tissue specificity:** BPC-157 has the broadest tissue research profile (GI, tendon, muscle, nerve, cardiovascular, liver, bone). TB-500 research focuses primarily on cardiac repair, wound healing, dermal regeneration, and corneal healing.

**Combination research:** Some investigators have studied BPC-157 and TB-500 in combination, hypothesizing complementary mechanisms. Preliminary data suggests additive effects on healing outcomes, though rigorous combination studies are limited.

As of early 2026, BPC-157 research continues to expand. Key areas of active investigation include:

**Neuropsychiatric models:** Recent publications have explored BPC-157 in models of traumatic brain injury, spinal cord injury, and neurodegenerative disease. The peptide's ability to interact with multiple neurotransmitter systems (dopaminergic, serotonergic, GABAergic) makes it a subject of interest in neuropsychopharmacology.

**Organ-protective effects:** Studies are investigating BPC-157's protective effects against drug-induced liver injury (acetaminophen, alcohol), kidney injury (cisplatin nephrotoxicity), and lung injury (bleomycin-induced fibrosis).

**Fistula and wound healing:** Clinical interest continues in the peptide's ability to promote closure of experimentally-induced fistulas (esophageal, colocutaneous) and complex wounds.

**Combination protocols:** Researchers are increasingly studying BPC-157 alongside other research peptides (TB-500, GHK-Cu) and alongside conventional therapies to evaluate potential synergistic effects.

**Limitations of current evidence:** The overwhelming majority of BPC-157 research comes from a single research group (Sikiric et al., University of Zagreb). While their work is extensive and methodologically sound, independent replication by other groups is limited. No completed human clinical trials exist. These are important caveats when evaluating the evidence base.